García-Bonetto GM, Nieto IR, Chapa R, Adrianzén C, Brnabic A, Meyers AL, Granger RE, Dossenbach M, Karagianis J, Ruíz I

Language: Spanish
References: 29
Page: 215-223
PDF size: 181.29 Kb.

ABSTRACT

Objective: this study assessed treatment outcomes of Latin American patients with bipolar I disorder (manic or mixed episodes) who included olanzapine in their treatment regimen compared with patients who did not. Materials and methods: patients from seven Latin American countries participated in this prospective, observational, noninterventional, open-label study conducted over 12 months. Main outcome measures were: (i) time to remission of manic symptoms (Young Mania Rating Scale (YMRS) ≤ 12), (ii) time to hospitalisation after remission, and (iii) time to relapse with a manic (YMRS ≥ 15) or depressive (MontgomeryÅsberg Depression Rating Scale (MADRS) ≥ 15) episode. Comparisons of clinical outcomes only included data from visits where patients continued to use their baseline treatment. Results: at baseline, 516 patients included olanzapine in their treatment and 246 did not; 67.5% of all patients had a manic episode and 31.9% had a mixed episode. Time to remission of manic symptoms was similar between groups (log-rank P-value = 0.133). Time to hospitalisation (log-rank P-value < 0.0001) and relapse with a manic (log-rank P value = 0.0002), but not a depressive (log-rank P-value = 0.363) episode was significantly longer in the olanzapine group compared with the non-olanzapine group. Similar rates of treatment-emergent adverse events and statistically significant improvements in quality of life (12-Item Short Form Health Survey) were observed in both groups. Conclusions: inclusion of olanzapine in bipolar I disorder therapy may allow patients from Latin America to maintain clinically effective and long-term responses to treatment.

REFERENCES

1. Hirschfeld RA, Bowden CL, Gitlin MJ, Keck PE, Suppes T, Thase ME, et al. Practice Guideline for the Treatment of Patients with Bipolar Disorder. Second edition. American Psychiatric Publishing, Inc., 2002.

2. Perlis RH, Ostacher MJ, Patel JK, Marangell LB, Zhang H, Wisniewski SR, et al. Predictors of recurrence in bipolar disorder: primary outcomes from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Am J Psychiatry 2006a;163:217-24.

3. Salvatore P, Tohen M, Khalsa HM, Baethge C, Tondo L, Baldessarini RJ. Longitudinal research on bipolar disorders. Epidemiol Psichiatr Soc 2007;16:109-17.

4. Tohen M, Sanger TM, McElroy SL, Tollefson GD, Chengappa KN, Daniel DG, et al. Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group. Am J Psychiatry 1999;156:702-9.

5. Tohen M, Jacobs TG, Grundy SL, McElroy SL, Banov MC, Janicak PG, et al. Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzipine HGGW Study Group. Arch Gen Psychiatry 2000;57:841-9.

6. Tohen M, Calabrese JR, Sachs GS, Banov MD, Detke HC, Risser R, et al. Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine. Am J Psychiatry 2006;163:247-56.

7. Tohen M, Ketter TA, Zarate CA, Suppes T, Frye M, Altshuler L, et al. Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study. Am J Psychiatry 2003a;160:1263-71.

8. Perlis RH, Baker RW, Zarate CA Jr, Brown EB, Schuh LM, Jamal HH, et al. Olanzapine versus risperidone in the treatment of manic or mixed States in bipolar I disorder: a randomized, double-blind trial. J Clin Psychiatry 2006b;67:1747-53.

9. Tohen M, Goldberg JF, Gonzalez-Pinto Arrillaga AM, Azorin JM, Vieta E, Hardy-Bayle MC, et al. A 12-week, double-blind comparison of olanzapine vs haloperidol in the treatment of acute mania. Arch Gen Psychiatry 2003b;60:1218-26.

10. Niufan G, Tohen M, Qiuqing A, Fude Y, Pope E, McElroy H, et al. Olanzapine versus lithium in the acute treatment of bipolar mania: a double-blind, randomized, controlled trial. J Affect Disord 2008;105:101-8.

11. Tohen M, Greil W, Calabrese JR, Sachs GS, Yatham LN, Oerlinghausen BM, et al. Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial. Am J Psychiatry 2005;162;1281-90.

12. Treuer T, Oruc L, Loza N, El Saidi MA, Kovacs Z, Akkaya C, et al. Acute phase results from STORM, a multicountry observational study of bipolar disorder treatment and outcomes. Psychiatr Danub 2007;19:282-95.

13. Vieta E, Panicali F, Goetz I, Reed C, Comes M, Tohen M, et al. Olanzapine monotherapy and olanzapine combination therapy in the treatment of mania: 12-week results from the European Mania in Bipolar Longitudinal Evaluation of Medication (EMBLEM) observational study. J Affect Disord 2008;106:63- 72.

14. Tamayo JM, Mazzotti G, Tohen M, Gattaz WF, Zapata R, Castillo JJ, et al. Outcomes for Latin American versus White patients suffering from acute mania in a randomized, double-blind trial comparing olanzapine and haloperidol. J Clin Psychopharmacol 2007;27:126-34.

15. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. Fourth edition, Text Revision (DSMIV- TR). Arlington VA: American Psychiatric Publishing, Inc., 2000.

16. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 1978;133:429-35.

17. Montgomery SA, Asberg MA. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-9.

18. 18.Ware J Jr, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care 1996:34;220-33.

19. Newgard CD, Hedges JR, Arthur M, Mullins RJ. Advanced statistics: the propensity score - a method for estimating treatment effect in observational research. Acad Emerg Med 2004;11:953-61.

20. Hernán MA, Brumback B, Robins JM. Marginal structural models to estimate the causal effect of zidovudine on the survival of HIVpositive men. Epidemiology 2000;11:561-70.

21. Altman DG, Andersen, PK. Calculating the number needed to treat for trials where the outcome is time to an event. BMJ 1999;319:1492-5.

22. Tohen M, Chengappa KN, Suppes T, Baker RW, Zarate CA, Bowden CL, et al. Relapse prevention in bipolar I disorder: 18- month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone. Br J Psychiatry 2004;184:337-45.

23. Hirschfeld RM, Lewis L, Vornik LA. Perceptions and impact of bipolar disorder: how far have we really come? Results of the national depressive and manic-depressive association 2000 survey of individuals with bipolar disorder. J Clin Psychiatry 2003;64:161-74.

24. Ghaemi SN, Hsu DJ, Thase ME, Wisniewski SR, Nierenberg AA, Miyahara S, et al. Pharmacological Treatment Patterns at Study Entry for the First 500 STEP-BD Participants. Psychiatr Serv 2006;57:660-5.

25. Michalak EE, Yatham LN, Lam RW. Quality of life in bipolar disorder: a review of the literature. Health Qual Life Outcomes 2005;3:72.

26. Salyers MP, Bosworth HB, Swanson JW, Lamb-Pagone J, Osher FC. Reliability and validity of the SF-12 health survey among people with severe mental illness. Med Care 2000;38:1141-50.

27. Vojta C, Kinosian B, Glick H, Altshuler L, Bauer MS. Self-reported quality of life across mood states in bipolar disorder. Compr Psychiatry 2001;42:190-5.

28. Faries D, Ascher-Svanum H, Belger M. Analysis of treatment effectiveness in longitudinal observational data. J Biopharm Stat 2007;17:809-26.

29. Joffe MM, Ten Have TR, Feldman HI, Kimmel SE. Model selection, confounder control, and marginal structural models: review and new applications. Am Stat 2004;58:272-9.